Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Kiichiro Toyoizumi · SciRah

Researcher profile · Semantic Scholar

Kiichiro Toyoizumi

Share profile

Kiichiro Toyoizumi — researcher profile on SciRah

h-index: 9
Works: 28
Citations: 973

Most-cited papers

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
M. Bassetti, R. Echols, Y. Matsunaga, M. Ariyasu +11 more
2020Lancet. Infectious Diseases (Print)602 citations
Semantic Scholar
A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
M. Ghadessi, R. Tang, Joey Tianyi Zhou, Rong Liu +6 more
2020Orphanet Journal of Rare Diseases156 citations Open access
Semantic Scholar
Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective
M. Ghadessi, Jun-Rui Di, Chenkun Wang, Kiichiro Toyoizumi +6 more
2023Orphanet Journal of Rare Diseases38 citations Open access
Semantic Scholar
Effects of Green Tea Gargling on the Prevention of Influenza Infection in High School Students: A Randomized Controlled Study
K. Ide, Hiroshi Yamada, Kumi Matsushita, Miki Ito +4 more
2014PLoS ONE33 citations Open access
Semantic Scholar
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
M. Bassetti, M. Ariyasu, B. Binkowitz, Tsutae Den Nagata +4 more
2019Infection and Drug Resistance29 citations Open access
Semantic Scholar
Perturbation theory with quantum signal processing
K. Mitarai, Kiichiro Toyoizumi, W. Mizukami
2022Quantum27 citations Open access
Semantic Scholar
Hamiltonian simulation using quantum singular value transformation: complexity analysis and application to the linearized Vlasov-Poisson equation
Kiichiro Toyoizumi, Naoki Yamamoto, K. Hoshino
202314 citations
Semantic Scholar
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.
K. Harrington, A. Rosenberg, Muh-Hwa Yang, J. Geiger +17 more
2025Oral Oncology12 citations Open access
Semantic Scholar
Gargling with Green Tea for Influenza Prophylaxis: A Pilot Clinical Study
Kiichiro Toyoizumi, Hiroshi Yamada, Keiji Matsumoto, Y. Sameshima
201310 citations Open access
Semantic Scholar
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
N. Matsubara, Yuji Miura, Hiroyuki Nishiyama, R. Taoka +10 more
2024International Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
Yumi Tsuchiya, Hiroshi Tamura, K. Fujii, Hirotaka Numaguchi +5 more
2023Vaccine8 citations Open access
Semantic Scholar
Effects of Short-Term Consumption of a Large Amount of Tea Catechins on Chromosomal Damage, Oxidative Stress Markers, Serum Lipid, Folic Acid, and Total Homocysteine Levels: A Randomized, Double-Blind, Controlled Study
T. Yoshikawa, Hiroshi Yamada, Katsuhiko Matsuda, H. Niino +9 more
20127 citations Open access
Semantic Scholar
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
D. Kotani, K. Yamaguchi, K. Kato, H. Hara +12 more
2024Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Quantum calculation for two-stream instability and advection test of Vlasov–Maxwell equations: numerical evaluation of Hamiltonian simulation
Hayato Higuchi, J. Pedersen, Kiichiro Toyoizumi, Kohji Yoshikawa +2 more
2024Journal of Plasma Physics6 citations Open access
Semantic Scholar
Hamiltonian simulation using the quantum singular-value transformation: Complexity analysis and application to the linearized Vlasov-Poisson equation
Kiichiro Toyoizumi, Naoki Yamamoto, K. Hoshino
2024Physical Review A6 citations
Semantic Scholar
Quantum conjugate gradient method using the positive-side quantum eigenvalue transformation
Kiichiro Toyoizumi, Kaito Wada, Naoki Yamamoto, K. Hoshino
20245 citations
Semantic Scholar
Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
S. Portsmouth, R. Echols, Kiichiro Toyoizumi, G. Tillotson +1 more
2021Therapeutic Advances in Infectious Disease5 citations Open access
Semantic Scholar
165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
Y. Matsunaga, M. Ariyasu, M. Takemura, Y. Yamano +4 more
2020Open Forum Infectious Diseases4 citations Open access
Semantic Scholar
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study
Barbara A. Burtness, Ari J. Rosenberg, B. Calderon, Sun M. Lim +30 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
N. Yamamoto, Y. Kuboki, K. Harano, T. Koyama +7 more
2024Investigational new drugs2 citations Open access
Semantic Scholar
Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
Barbara A. Burtness, K. Harrington, Dong-Mei Ji, B. Calderon +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
M. Bassetti, R. Echols, Y. Matsunaga, S. Portsmouth +4 more
2020Open Forum Infectious Diseases1 citations Open access
Semantic Scholar
Correcting Estimation Bias in Randomized Clinical Trials With a Test of Treatment-by-Biomarker Interaction
Kiichiro Toyoizumi, S. Matsui
20171 citations Open access
Semantic Scholar
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.
Hsiang-Fong Kao, K. Harrington, A. Bhatia, Hung-Ming Wang +23 more
2026Clinical Cancer Research0 citations Open access
Semantic Scholar
Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials
Kiichiro Toyoizumi, S. Matsui
2022Statistics in Medicine0 citations
Semantic Scholar
1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin
David PatersonDavid PatersonMasahiro Kinoshita, Kiichiro Toyoizumi, Y. Matsunaga, R. Echols
2020Open Forum Infectious Diseases0 citations Open access
Semantic Scholar
1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study
S. Portsmouth, Kiichiro Toyoizumi, Tsutae Den Nagata, G. Tillotson +1 more
2019Open Forum Infectious Diseases0 citations Open access
Semantic Scholar
Biomarker-Based Phase II and III Clinical Trials in Oncology
S. Matsui, M. Igeta, Kiichiro Toyoizumi
2019Textbook of Clinical Trials in Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Echols×7
Invite
R. Echols — researcher profile on SciRah
Y. Matsunaga×5
Invite
Y. Matsunaga — researcher profile on SciRah
Tsutae Den Nagata×5
Invite
Tsutae Den Nagata — researcher profile on SciRah
M. Ariyasu×4
Invite
M. Ariyasu — researcher profile on SciRah

×4

Invite

S. Portsmouth — researcher profile on SciRah

J. C. Curtin×4

Invite

J. C. Curtin — researcher profile on SciRah

Invite

Mark Wade — researcher profile on SciRah

Emrullah Yilmaz×4

Invite

Emrullah Yilmaz — researcher profile on SciRah

P. Swiecicki×4

Invite

P. Swiecicki — researcher profile on SciRah

Invite

M. Bassetti — researcher profile on SciRah

Invite

Y. Doi — researcher profile on SciRah

Keiji Matsumoto×3

Invite

Keiji Matsumoto — researcher profile on SciRah